全球最小残留病检测市场研究报告-2023-2030 年行业分析、规模、份额、增长、趋势和预测

全球对微小残留病检测市场的需求将从 2022 年的 61.1 亿美元增长到 2030 年的近 402.4 亿美元，复合年增长率为 26.57%，预计 2023-2030 年研究期间将达到

微小残留病检测是一种用于检测治疗后残留在体内的少量癌细胞的方法。 MRD 测试可以帮助监测癌症治疗的有效性并预测復发的可能性。 MRD 检测的目标是儘早检测癌细胞，当它们仍处于低水平且尚未形成可见肿瘤时。

市场动态：

癌症发病率的增加推动了对 MRD 检测的需求。 随着癌症患者人数的不断增加，越来越多的患者被诊断出癌症并接受治疗，从而增加了对 MRD 检测的需求。 患者和医疗保健专业人员对 MRD 检测意识的提高也推动了市场增长。 此外，政府对癌症研究和新癌症治疗方法的支持也推动了 MRD 检测市场的增长。 与此同时，用于 MRD 检查的新敏感技术的开发正在推动市场增长。 然而，测试的成本和可用性可能会限制市场增长。

研究报告描述了波特的五力模型、市场吸引力分析和价值链分析。 这些工具可帮助您清楚地了解您的行业结构并评估您在全球范围内的竞争吸引力。 此外，这些工具还可以对全球微小残留病检测市场的每个细分市场进行全面评估。 微小残留病检测行业的发展和趋势为这项研究提供了一种整体方法。

市场细分：

本部分按国家/地区提供详细的细分数据，以帮助您确定每种产品/服务的目标受众和未来商机。

按癌症类型

• 流式细胞仪
• 聚合□炼式反应 (PCR)
• 下一代测序 (NGS)
• 其他

技术

• 血液系统恶性肿瘤（淋巴瘤、白血病）
• 实体癌

按最终用途

• 医院和专科诊所
• 诊断实验室
• 学术和研究机构
• 其他

按地区分析：

本节涵盖区域展望，重点介绍北美、欧洲、亚太地区、拉丁美洲、中东和非洲对微小残留病检测市场当前和未来的需求。 此外，它还关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的综合概况和全球竞争格局的详细视图。 最小残留疾病检测市场的主要参与者是 Exact Sciences Corporation、Grail LLC、Veracyte Inc.、Natera Inc.、Guardant Health、F. Hoffmann-La Roche Ltd、Foundation Medicine Inc.、Qiagen、mdxhealth、Bio-Techne。 本节概述了竞争格局，包括各种战略发展，例如主要併购、未来能力、合作伙伴关係、财务概览、合作、新产品开发和新产品发布。

如果您有定制要求，请联繫我们。 我们的研究团队可以根据您的需要提供定制报告。

内容

第一章前言

• 本报告的内容
  • 目的
  • 目标受众
  • 独特的销售建议 (USP) 和提供的服务
• 调查范围
• 调查方法
  • 市场调研过程
  • 市场研究方法

第 2 章执行摘要

• 市场亮点
• 全球市场概况

第 3 章最小残留病检测 - 行业分析

• 简介 - 市场动态
• 市场驱动因素
• 市场製约因素
• 市场机会
• 行业趋势
• 波特的五力分析
• 市场吸引力分析
  • 按癌症类型进行市场吸引力分析
  • 按技术进行市场吸引力分析
  • 市场吸引力分析：按最终用途
  • 市场吸引力分析：按地区

第四章价值链分析

• 价值链分析
• 原材料分析
  • 成分錶
  • 原材料製造商列表
  • 主要原材料价格走势
• 潜在买家名单
• 营销渠道
  • 直接营销
  • 间接营销
  • 营销渠道趋势

第 5 章 COVID-19 爆发的影响分析

第 6 章微量残留病检测的全球市场分析：癌症类型

• 癌症类型总结
• 实际数据和预测数据
• 按癌症类型分析
• 流式细胞仪
• 聚合□炼式反应 (PCR)
• 下一代测序 (NGS)
• 其他

第 7 章全球最小残留病检测市场分析：按技术分类

• 技术概述
• 实际数据和预测数据
• 技术分析
• 血液系统恶性肿瘤（淋巴瘤、白血病）
• 实体瘤

第 8 章最小残留病检测的全球市场销售分析：按最终用途

• 按最终用途汇总
• 实际数据和预测数据
• 最终用途分析
• 医院和专科诊所
• 诊断实验室
• 学术和研究机构
• 其他

第 9 章微量残留病检测的全球市场销售分析：按地区

• 按地区进行的销售前景分析
• 介绍销售分析
• 北美销售分析
  • 概览、历史和预测销售分析
  • 北美各部门的销售分析
  • 北美销售分析
  • 美国销售分析
  • 加拿大销售分析
  • 墨西哥销售分析
• 欧洲销售分析
  • 概览、历史和预测销售分析
  • 按细分市场进行的欧洲销售分析
  • 按国家/地区划分的欧洲销售分析
  • 英国销售分析
  • 法国销售分析
  • 德国销售分析
  • 意大利销售分析
  • 俄罗斯销售分析
  • 其他欧洲销售分析
• 亚太地区销售分析
  • 概览、历史和未来销售分析
  • 亚太地区各部门的销售分析
  • 亚太国家/地区销售分析
  • 在中国的销售分析
  • 印度销售分析
  • 日本的销售分析
  • 韩国销售分析
  • 澳大利亚销售分析
  • 其他亚太地区销售分析
• 拉丁美洲销售分析
  • 概览、历史和未来销售分析
  • 拉丁美洲各部门的销售分析
  • 拉丁美洲国家/地区的销售分析
  • 巴西销售分析
  • 阿根廷销售分析
  • 秘鲁销售分析
  • 智利的销售分析
  • 其他拉丁美洲销售分析
• 中东和非洲销售分析
  • 概览、历史和未来销售分析
  • 中东/非洲地区的销售分析
  • 中东和非洲国家/地区的销售分析
  • 沙特阿拉伯销售分析
  • 阿联酋销售分析
  • 以色列销售分析
  • 南非销售分析
  • 其他中东和非洲销售分析

第10章微小残留病检测企业竞争状况

• 最小残留病检测市场竞争
• 伙伴关係、合作、协议
• 併购
• 新产品发布
• 其他发展

第11章公司简介

• 前 10 名公司的市场份额分析
• 市场集中度
• 精确科学公司
  • 公司简介
  • 企业收入
  • 产品介绍
  • 近期发展状况
• 圣杯有限责任公司
  • 公司简介
  • 企业收入
  • 产品信息
  • 近期发展状况
• Veracyte 公司
  • 公司简介
  • 企业收入
  • 产品信息
  • 近期发展状况
• Natera 公司
  • 公司简介
  • 企业收入
  • 产品信息
  • 近期发展状况
• 守护健康
  • 公司简介
  • 企业收入
  • 产品信息
  • 近期发展状况
• F. Hoffmann-La Roche Ltd.
  • 公司简介
  • 企业收入
  • 产品信息
  • 近期发展状况
• Foundation Medicine Inc.
  • 公司简介
  • 企业收入
  • 产品信息
  • 近期发展状况
• 恰根
  • 公司简介
  • 企业收入
  • 产品信息
  • 近期发展状况
• mdx 健康
  • 公司简介
  • 企业收入
  • 产品信息
  • 近期发展状况
• 生物技术
  • 公司简介
  • 企业收入
  • 产品信息
  • 近期趋势

注意：公司简介中的财务细节和近期发展基于可用信息，可能不包括私营公司。

The global demand for Minimal Residual Disease Testing Market is presumed to reach the market size of nearly USD 40.24 BN by 2030 from USD 6.11 BN in 2022 with a CAGR of 26.57% under the study period 2023 - 2030.

Minimal residual disease testing is a method used to detect small amounts of cancer cells remaining in the body after treatment. MRD testing is used to monitor the effectiveness of cancer treatment and to help predict the likelihood of relapse. The goal of MRD testing is to detect cancer cells at the earliest possible stage when they are still at a low level and have not yet formed a visible tumour. 

Market Dynamics:

The increasing incidence of cancer is driving demand for MRD testing. As cancer cases continue to rise, more patients are being diagnosed and treated for cancer, which is increasing the demand for MRD testing. The growing awareness about MRD testing among patients and healthcare professionals is also driving growth in the market. Furthermore, government support for cancer research and the developing of new cancer therapies is driving growth in the MRD testing market. Along with this, developing new and more sensitive technologies for MRD testing is driving growth in the market. However, the cost and availability of the test may limit the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of minimal residual disease testing. The growth and trends of minimal residual disease testing industry provide a holistic approach to this study. 

Market Segmentation:

This section of the minimal residual disease testing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities. 

By Cancer Type

• Flow Cytometry
• Polymerase Chain Reaction (PCR)
• Next Generation Sequencing (NGS)
• Others

By Technology

• Hematological Malignancy (Lymphoma, Leukemia)
• Solid Tumors

By End-Use

• Hospitals And Specialty Clinics
• Diagnostic Laboratories
• Academic And Research Institutes
• Others

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Minimal Residual Disease Testing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the minimal residual disease testing market include Exact Sciences Corporation, Grail LLC, Veracyte Inc., Natera Inc., Guardant Health, F. Hoffmann-La Roche Ltd, Foundation Medicine Inc., Qiagen, mdxhealth, Bio-Techne. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . MINIMAL RESIDUAL DISEASE TESTING - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Cancer Type
  • 3.7.2 Market Attractiveness Analysis By Technology
  • 3.7.3 Market Attractiveness Analysis By End-Use
  • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET ANALYSIS BY CANCER TYPE

• 6.1 Overview by Cancer Type
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Cancer Type
• 6.4 Flow Cytometry Historic and Forecast Sales by Regions
• 6.5 Polymerase Chain Reaction (PCR) Historic and Forecast Sales by Regions
• 6.6 Next Generation Sequencing (NGS) Historic and Forecast Sales by Regions
• 6.7 Others Historic and Forecast Sales by Regions

7 . GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET ANALYSIS BY TECHNOLOGY

• 7.1 Overview by Technology
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Technology
• 7.4 Hematological Malignancy (Lymphoma, Leukemia) Historic and Forecast Sales by Regions
• 7.5 Solid Tumors Historic and Forecast Sales by Regions

8 . GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SALES ANALYSIS BY END-USE

• 8.1 Overview by End-Use
• 8.2 Historical and Forecast Data
• 8.3 Analysis by End-Use
• 8.4 Hospitals And Specialty Clinics Historic and Forecast Sales by Regions
• 8.5 Diagnostic Laboratories Historic and Forecast Sales by Regions
• 8.6 Academic And Research Institutes Historic and Forecast Sales by Regions
• 8.7 Others Historic and Forecast Sales by Regions

9 . GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SALES ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook Sales Analysis
• 9.2. Introduction Sales Analysis
• 9.3. North America Sales Analysis
  • 9.3.1. Overview, Historic and Forecast Sales Analysis
  • 9.3.2. North America By Segment Sales Analysis
  • 9.3.3. North America By Country Sales Analysis
  • 9.3.4. United State Sales Analysis
  • 9.3.5. Canada Sales Analysis
  • 9.3.6. Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1. Overview, Historic and Forecast Sales Analysis
  • 9.4.2. Europe by Segment Sales Analysis
  • 9.4.3. Europe by Country Sales Analysis
  • 9.4.4. United Kingdom Sales Analysis
  • 9.4.5. France Sales Analysis
  • 9.4.6. Germany Sales Analysis
  • 9.4.7. Italy Sales Analysis
  • 9.4.8. Russia Sales Analysis
  • 9.4.9. Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1. Overview, Historic and Forecast Sales Analysis
  • 9.5.2. Asia Pacific by Segment Sales Analysis
  • 9.5.3. Asia Pacific by Country Sales Analysis
  • 9.5.4. China Sales Analysis
  • 9.5.5. India Sales Analysis
  • 9.5.6. Japan Sales Analysis
  • 9.5.7. South Korea Sales Analysis
  • 9.5.8. Australia Sales Analysis
  • 9.5.9. Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1. Overview, Historic and Forecast Sales Analysis
  • 9.6.2. Latin America by Segment Sales Analysis
  • 9.6.3. Latin America by Country Sales Analysis
  • 9.6.4. Brazil Sales Analysis
  • 9.6.5. Argentina Sales Analysis
  • 9.6.6. Peru Sales Analysis
  • 9.6.7. Chile Sales Analysis
  • 9.6.8. Rest of Latin America Sales Analysis
• 9.7. Middle East & Africa Sales Analysis
  • 9.7.1. Overview, Historic and Forecast Sales Analysis
  • 9.7.2. Middle East & Africa by Segment Sales Analysis
  • 9.7.3. Middle East & Africa by Country Sales Analysis
  • 9.7.4. Saudi Arabia Sales Analysis
  • 9.7.5. UAE Sales Analysis
  • 9.7.6. Israel Sales Analysis
  • 9.7.7. South Africa Sales Analysis
  • 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE MINIMAL RESIDUAL DISEASE TESTING COMPANIES

• 10.1. Minimal Residual Disease Testing Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11 . COMPANY PROFILES OF MINIMAL RESIDUAL DISEASE TESTING INDUSTRY

• 11.1. Top 10 Company Share Analysis
• 11.2. Market Concentration Rate
• 11.3. Exact Sciences Corporation
  • 11.3.1. Company Overview
  • 11.3.2. Company Revenue
  • 11.3.3. Products
  • 11.3.4. Recent Developments
• 11.4. Grail LLC
  • 11.4.1. Company Overview
  • 11.4.2. Company Revenue
  • 11.4.3. Products
  • 11.4.4. Recent Developments
• 11.5. Veracyte Inc.
  • 11.5.1. Company Overview
  • 11.5.2. Company Revenue
  • 11.5.3. Products
  • 11.5.4. Recent Developments
• 11.6. Natera Inc.
  • 11.6.1. Company Overview
  • 11.6.2. Company Revenue
  • 11.6.3. Products
  • 11.6.4. Recent Developments
• 11.7. Guardant Health
  • 11.7.1. Company Overview
  • 11.7.2. Company Revenue
  • 11.7.3. Products
  • 11.7.4. Recent Developments
• 11.8. F. Hoffmann-La Roche Ltd
  • 11.8.1. Company Overview
  • 11.8.2. Company Revenue
  • 11.8.3. Products
  • 11.8.4. Recent Developments
• 11.9. Foundation Medicine Inc.
  • 11.9.1. Company Overview
  • 11.9.2. Company Revenue
  • 11.9.3. Products
  • 11.9.4. Recent Developments
• 11.10. Qiagen
  • 11.10.1. Company Overview
  • 11.10.2. Company Revenue
  • 11.10.3. Products
  • 11.10.4. Recent Developments
• 11.11. mdxhealth
  • 11.11.1. Company Overview
  • 11.11.2. Company Revenue
  • 11.11.3. Products
  • 11.11.4. Recent Developments
• 11.12. Bio-Techne
  • 11.12.1. Company Overview
  • 11.12.2. Company Revenue
  • 11.12.3. Products
  • 11.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Cancer Type (USD MN)
• Flow Cytometry Market Sales by Geography (USD MN)
• Polymerase Chain Reaction (PCR) Market Sales by Geography (USD MN)
• Next Generation Sequencing (NGS) Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Analysis Market by Technology (USD MN)
• Hematological Malignancy (Lymphoma, Leukemia) Market Sales by Geography (USD MN)
• Solid Tumors Market Sales by Geography (USD MN)
• Analysis by End-Use (USD MN)
• Hospitals And Specialty Clinics Market Sales by Geography (USD MN)
• Diagnostic Laboratories Market Sales by Geography (USD MN)
• Academic And Research Institutes Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Minimal Residual Disease Testing Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Minimal Residual Disease Testing Report
• Market Research Process
• Market Research Methodology
• Global Minimal Residual Disease Testing Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Cancer Type
• Market Attractiveness Analysis by Technology
• Market Attractiveness Analysis by End-Use
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Cancer Type (USD MN)
• Flow Cytometry Market Sales by Geography (USD MN)
• Polymerase Chain Reaction (PCR) Market Sales by Geography (USD MN)
• Next Generation Sequencing (NGS) Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market Analysis by Technology (USD MN)
• Hematological Malignancy (Lymphoma, Leukemia) Market Sales by Geography (USD MN)
• Solid Tumors Market Sales by Geography (USD MN)
• Global Market Analysis by End-Use (USD MN)
• Hospitals And Specialty Clinics Market Sales by Geography (USD MN)
• Diagnostic Laboratories Market Sales by Geography (USD MN)
• Academic And Research Institutes Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market by Revenue
• North America Market by Revenue
• Europe Market by Revenue
• Asia Pacific Market by Revenue
• Latin America Market by Revenue
• Middle East & Africa Market by Revenue
• Recent Development in Industry
• Top Company Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.